Skip to main content
SpringerLink
Log in

OPC-8212 in the treatment of congestive heart failure: Results of a pilot study

  • Congestive Heart Failure
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

To characterize the effects of OPC-8212, a quinolone inotropic agent, in patients with heart failure, we utilized invesive homodynamics, exercise testing, 24-hour ambulatory electrocardiograms, and two patient self-assessment questionnaires, before and after 1 month of treatment with OPC-8212, in 17 patients with moderate to severe congestive heart failure. There were no significant changes from baseline in heart rate (83±8 beats/min), mean arterial pressure (70±15 mmHg), pulmonary wedge pressure (18±7 mmHg), or cardiac index (2.3±0.4 L/min/m2) following treatment with OPC-8212. Both exercise duration (5.3±1.6 min) and peak oxygen consumption (12.0±2.9 mL/kg/min) were unchanged by OPC-8212. Two independent patient self-assessment scores, the Sickness Impact Profile and the Minnesota Living with Heart Failure Questionnaire, showed improvements from 6.8 to 5.4 and 49 to 38, respectively (both p<.05), suggesting that the patients reported an improvement in daily functioning. The median ventricular premature contraction count and frequency were reduced from 1,118 beats to 243 beats (p<0.05) and 11/1,000 beats to 2,4/1,000 beats (0.05<p<0.10), respectively. Two patients developed agranulocytosis during longer-term treatment following this 1-month study. These data demonstrate that OPC-8212 did not have significant effects on hemodynamics or exercise tolerance. However, the improvement in patient self-assessment scores and the trend for improvement in ventricular arrhythmia profiles suggest that OPC-8212 may have some benefit for patients with congestive heart failure, but additional placebo-controlled, double-blind studies are necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maskin CS, Sinoway L, Chadwick B, et al. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severs congestive heart failure. Circulation 1983;67:1065–1070.

    Google Scholar 

  2. Kubo SH, Cody RJ, Chatterjee K, et al. Acute dose range study of milrinone in conjestive heart failure. Am J Cardiol 1985;55:726–730.

    Google Scholar 

  3. Simonton CA, Chaterjee K, Cody RJ, et al. Milrinone in congestive heart failure: Acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol 1985;6:453–459.

    Google Scholar 

  4. Massie B, Bourassa M, Di Bianco R, et al. Long-term oral administration of amrinone for congestive heart failure: Lack of afficacy in a multicenter controlled trial. Circulation 1985;71:963–971.

    Google Scholar 

  5. Leier CV, Dalpiaz K, Huss P, et al. Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. Am J Cardiol 1983;52:304–308.

    Google Scholar 

  6. Holmes JR, Kubo SH, Cody RJ, Kligfield P. Milrinone in congestive heart failure: Observations on ambulatory ventricular arrhythmias. Am Heart J 1985;110:800–806.

    Google Scholar 

  7. Ludmer PL, Baim DS, Antman EM, et al. Effects of milrinene on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1987;59:1351–1355.

    Google Scholar 

  8. Goldstein RA, Geraci SA, Gray EL, et al. Electrophysiologic effects of milrinone in patients with congestive heart failure. Am J Cardiol 1986;57:624–628.

    Google Scholar 

  9. Packer M, Leier CV. Survival in congestive heart failure during treatment with drugs with positive inotropic actiona. Circulation 1987;75(Suppl IV):IV-55-IV-63.

    Google Scholar 

  10. Sasayama S, Inoue M, Asanoi H, et al. Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure. Heart Vessels 1986;2:23–28.

    Google Scholar 

  11. Asanoi H, Sasayama S, Iuchi K, Kameyama T. Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure. J Am Coll Cardiol 1987;9:865–871.

    Google Scholar 

  12. Inoue M, Kim BH, Hori M, et al. Oral OPC-8212 for the treatment of congestive heart failure: Hemodynamic improvement and increased exercise capacity. Heart Vessels 1986;2:166–171.

    Google Scholar 

  13. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: Development and final revision of a health status measure. Med Care 1981;19:787–805.

    Google Scholar 

  14. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure: II: Content, reliability and validity of a new measure-The Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;3:198–209.

    Google Scholar 

  15. Passon PG, Peuler JD. A simplified radiometric assay for norepinephrine and epinephrine. Anal Biochem 1973;51: 613–631.

    Google Scholar 

  16. Grupp G, Grupp IL, Newman G, Schwartz A. Effects of a new positive inotropic agent, 3,4-dihydro-β-[4-(3,4-demethoxybenzoyl) 1-piperanzinyl]-2(1H)-quinolons (OPC-8212), and its solvent, sulfolane, on isolated heart preparstions of the rat, guinea pigs and dog. Arzneimittel Forschung 1984;34:359–363.

    Google Scholar 

  17. Hori M, Inoue M, Tamai J, et al. Cardiotonic activity of a new inotropic agent, 3,4-Dihydro-6-[4-(3,4-dimethoxybenzoyl) 1-piperanzinyl]-2(1H)-quinolinone (OPC-8212), in the dog with and without beta-blocker and CA++ antagonist pretreatment. Jpn Circ J 1986;50:37–44.

    Google Scholar 

  18. Taira N, Endoh M, Iljima T, et al. Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-demethoxybenzoyl) 1-piperanzinyl]-2(1H)-quinolone (OPC-8212), a novel positive inotropic drug, on the dog heart. Arzneimittel Forachung 1984; 34:347–355.

    Google Scholar 

  19. Yanagisawa T, Endoh M, Taira N. Involvement of cyclic AMP in the positive inotropic effect of OPC-8212, a new cardiotonic agent, on the canine ventricular muscle. Jpn J Pharmacol 1984;36:379–388.

    Google Scholar 

  20. Endoh M, Yanagisawa T, Taira N, Blinks JR. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation 1986;73(Suppl III):III-117-III-133.

    Google Scholar 

  21. Grupp G, Grupp IL, Kojima M, et al. Hemodynamic and electrophysiological effects of a novel positive inotropic drug, OPC-8212, in normal and “failing” guinea pig heart preparations. J Cardiovasc Pharmacol 1986;8:428–440.

    Google Scholar 

  22. Lathrop DA, Schwartz A. Evidence for possible increase of sodium channel open time and involvement of Na/Ca exchange by a new positive inotropic drug: OPC-8212. Eur J Pharmacol 1985;117:391–392.

    Google Scholar 

  23. Ijima T, Taira N. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. J Pharmacol Exp Ther 1987;240:657–662.

    Google Scholar 

  24. Imoto Y, Yatani A, Schwartz A, Brown AM. Properties of the effects of a new positive inotropie drug, OPC-8212 on single Ca channels (abstr). Circulation 1987;IV-474.

  25. Rector TS, Francis GS, Cohn JN. Patients' self-assessment of their congestive heart failure: I. Patient perceived dysfunction and its poor correlation with maximal exercise tests. Heart Failure 1987;3:188–191.

    Google Scholar 

  26. Morganroth J, Michelson EL, Horowitz LN, et al. Limitations of routine long term electrocardiographic monitoring to assess ventricular ectopic frequency. Circulation 1978; 58:408.

    Google Scholar 

  27. Hashimoto K, Mitsuhashi H. Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias, Br J Pharmacol 1986;88:915–921.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Minnesota, Minneapolis

    Spencer H. Kubo, Thomas S. Rector & Jay N. Cohn

  2. Valley Hospital, Ridgewood, New Jersey

    John E. Strobeck

Authors
  1. Spencer H. Kubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas S. Rector
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John E. Strobeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jay N. Cohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kubo, S.H., Rector, T.S., Strobeck, J.E. et al. OPC-8212 in the treatment of congestive heart failure: Results of a pilot study. Cardiovasc Drug Ther 2, 653–660 (1988). https://doi.org/10.1007/BF00054205

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00054205

Key words

Search

Navigation